Recent data from Gautheron and colleagues found that the concentration of RIP1 and MLKL increased in patients with NASH dependent on disease severity (9), but this study only evaluated circulating RIP1 and MLKL in patients with different severities of NASH, without inclusion of HCs (9). Here, MLKL is linked to metabolic dysfunction-associated steatohepatitis.